

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/596,930	Inventors: Ashwell et al.
Filing Date: June 29, 2006	Attorney Docket No.: 101367-P US/O
Examiner: Jean-Louis Samira J.	Group Art Unit : 1627
Customer No.: 44992	Confirmation No.: 2429
Title: Thiophene derivatives as CHK 1 Inhibitors	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir,

Applicant submits herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. §1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. §1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. §1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. §1.114.
- ☒ (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. §1.311, and
- ☐ the requisite Statement is below, **OR**
- ☒ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. §1.17(p), namely **\$180.00** to deposit account No. **50-3231**, referencing Attorney Docket No. 101367-1P US/O.
- ☐ (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee, AND**
- ☐ the requisite Statement is below, **OR**
- ☐ the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. §1.17(p), namely **\$180.00** to deposit account No. 50-3231, referencing Attorney Docket No.

Applicant hereby makes the following additional information of record in the above-identified application:

The present Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, of which the following is a concise explanation:
- ☐ Includes an English Abstract and/or a Title of a non-English citation.
- ☐ Includes one or more translations of a non-English citation.

Applicant respectfully requests that the documents filed herewith, including each of the patents and publications listed on the attached Form SB08, be considered and acknowledged; and further requests that the Examiner place initials after each of the patents and publications, to indicate that appropriate consideration of each was made during examination.

Applicant invites the Examiner to contact the undersigned, Julie Anne Knight, at (781) 839-4002, with any questions pertaining to the above-identified application in order to expedite prosecution of this case.

For purposes of clarity, **no authorization is given to charge other fees not essential to maintain pendency of the above-identified application.** Should the United States Patent and Trademark Office be of the view that such non-essential fees are owed, a Notice specifically itemizing and requesting payment of such fees is requested.

/Julie Anne Knight/

Name: Julie Anne Knight
Dated: **April 27, 2011**
Reg. No.: 48,867
Phone No.: (781) 839-4002
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451